The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | GI cancer highlights at ASCO 2026: EGFR-HER3 bispecifics and RASolute 302
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the promising data presented during the oral abstracts at the 2026 American Society of Clinical Oncology (ASCO) Meeting, including the emergence of EGFR-HER3 bispecifics for gastric cancer in later line settings and advancements in the HER2 space in colorectal cancer. The RASolute 302 (NCT06625320) additionally showed promise in targeting metastatic pancreatic ductal adenocarcinoma (PDAC). This interview took place during the 2026 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Today was the oral abstracts in gastric, and we saw a lot of interesting data from China for EGFR HER3 bispecific in later line settings. We’re also seeing very interesting data, of course, in the HER2 space, in colorectal cancer we saw. And what’s interesting is a lot of the assets are coming from Asia, from China. And we need to be aware of this data. And some of it may be directly translatable to our patients...
Today was the oral abstracts in gastric, and we saw a lot of interesting data from China for EGFR HER3 bispecific in later line settings. We’re also seeing very interesting data, of course, in the HER2 space, in colorectal cancer we saw. And what’s interesting is a lot of the assets are coming from Asia, from China. And we need to be aware of this data. And some of it may be directly translatable to our patients. In some cases, we may need to do additional studies for confirmation. But the plenary was inspiring. And I think all of the space now is reinvigorated and very hopeful because, of course, we are successfully targeting and overcame treatment barriers in pancreatic cancer, which is for RAS mutant tumors. And so we’re interested in looking for RAS targeting across tumor types, including gastric, of course, colorectal cancer, where it’s very promising.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
